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Background: Because of the role of inflammation in preterm birth (PTB), polymorphisms in and near the
interleukin-6 gene (IL6) have been association study targets. Several previous studies have assessed the association
between PTB and a single nucleotide polymorphism (SNP), rs1800795, located in the IL6 gene promoter region.
Their results have been inconsistent and SNP frequencies have varied strikingly among different populations. We
therefore conducted a meta-analysis with subgroup analysis by population strata to: (1) reduce the confounding
effect of population structure, (2) increase sample size and statistical power, and (3) elucidate the association
between rs1800975 and PTB.
Results: We reviewed all published papers for PTB phenotype and SNP rs1800795 genotype. Maternal genotype
and fetal genotype were analyzed separately and the analyses were stratified by population. The PTB phenotype
was defined as gestational age (GA) < 37 weeks, but results from earlier GA were selected when available. All
studies were compared by genotype (CC versus CG+GG), based on functional studies.
For the maternal genotype analysis, 1,165 PTBs and 3,830 term controls were evaluated. Populations were stratified
into women of European descent (for whom the most data were available) and women of heterogeneous origin or
admixed populations. All ancestry was self-reported. Women of European descent had a summary odds ratio (OR)
of 0.68, (95% confidence interval (CI) 0.51 – 0.91), indicating that the CC genotype is protective against PTB. The
result for non-European women was not statistically significant (OR 1.01, 95% CI 0.59 - 1.75). For the fetal genotype
analysis, four studies were included; there was no significant association with PTB (OR 0.98, 95% CI 0.72 - 1.33).
Sensitivity analysis showed that preterm premature rupture of membrane (PPROM) may be a confounding factor
contributing to phenotype heterogeneity.
Conclusions: IL6 SNP rs1800795 genotype CC is protective against PTB in women of European descent. It is not
significant in other heterogeneous or admixed populations, or in fetal genotype analysis.
Population structure is an important confounding factor that should be controlled for in studies of PTB.
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Preterm birth (PTB) is defined as birth before 37 com-
pleted weeks’ gestation. Prematurity is the leading cause
of neonatal mortality in newborns without congenital
anomalies or chromosomal abnormalities [1,2]. It is also
associated with a broad spectrum of lifelong morbidity
in survivors, including neurodevelopmental delay, cere-
bral palsy, blindness, deafness, and chronic lung disease
[3,4]. Despite efforts to reduce preterm birth, the rate
has remained relatively stable over the last few decades and
was 11.7% in the United States in 2011 [1,5]. Although PTB
is a pressing public health issue, the incomplete understand-
ing of genetic and environmental risk factors has
inhibited development of effective prevention and
treatment strategies.
The etiology of PTB is complex and multifactorial [6-9].
There is compelling evidence that both maternal and fetal
genomes contribute to risk [10-12], and PTB prevalence
varies among population groups [13-17]. African-American
ancestry is consistently associated with an increased risk of
preterm birth even after adjusting for epidemiologic risk
factors, such as income, education, lack of prenatal care,
and other socioeconomic factors [6,18,19]. The heritability
of PTB, based on twin studies, is estimated to be approxi-
mately 30% [20-22].
Despite strong evidence of a genetic component, con-
sistent identification of risk loci has been challenging. A
promising candidate gene has been interleukin-6 (IL6).
This gene encodes the pro-inflammatory cytokine
interleukin-6 (IL-6), which is involved in the regulation
of innate immunity. Several studies have shown that
PTB is associated with increased concentration of IL-6
in maternal serum, cervicovaginal secretions and amni-
otic fluid [23-25]. Many IL6 polymorphisms have been
assessed for association with preterm birth [26]. A single
nucleotide polymorphism (SNP), rs1800795, usually re-
ferred to as IL6 -174 (from the transcription start site)
or −237 (from the translation start site), is located within
the IL6 promoter region [27,28] and is one of the most
thoroughly studied IL6 variants. This SNP is located in
the segment of the IL6 promoter that is crucial for tran-
scriptional induction with viruses and other cytokines
[27,28]. Expression studies of IL-6 with allelic variants of
the rs1800795 polymorphism have produced different
results in different tissues [29-31]. Nevertheless, studies
using HeLa cell lines showed that the derived C-allele is
associated with a significantly lower level of IL6 expres-
sion (0.624-fold lower) [32]. In addition, adults with the
CC genotype have significant lower plasma concentra-
tions of IL-6, compared with adults with the GG or GC
genotypes (1.63 pg/mL v.s. 2.74 or 2.64 pg/mL) [32].
Studies of the association between the IL6 rs1800795
polymorphism and PTB have yielded inconsistent results.
Simhan et al. (2003) reported that the CC genotype isprotective for PTB compared to the CG and GG geno-
types [33]. However, others [34-44] have shown no signifi-
cant association between IL6 and PTB. Hapmap data
show that the C allele has a frequency of 0.53 in the CEU
population (Utah residents with ancestry from northern
and western Europe), but it is absent in the YRI (Yoruba
in Ibadan, Nigeria), CHB (Han Chinese in Beijing, China)
and JPT (Japanese in Tokyo, Japan) populations [45]. Be-
cause previous studies have been limited by small sample
size and by potential population stratification, we hypothe-
sized that the inconsistent results for rs1800795 are, at
least in part, explained by differences in population struc-
ture and admixture. Here, we carry out a meta-analysis to
systematically review the association of rs1800795 with
spontaneous PTB, and to specifically explore the SNP as-
sociation within population strata.
Results
Included studies
Thirty-three articles were identified from the initial
keywords search. After review, 21 were excluded (see
Additional file 1). Table 1a and 1b summarize the char-
acteristics of the studies included in the meta-analysis,
including study populations, whether or not preterm
premature rupture of membrane (PPROM) was ex-
cluded, cutoff for the cases and controls, and sample
sizes (Table 1a and 1b). For maternal genotype ana-
lysis, a total of ten studies were included. This resulted
in 1,165 PTB cases and 3,830 term controls, more than
tripling the case sample size of any individual study
(Table 1a). For the fetal analysis, only four studies
could be included, with 785 PTB cases and 882 term
controls (Table 1b).
Each study was stratified by population into (1) European
ancestry or (2) heterogeneous population – either the stu-
died samples were from admixed populations or contained
several different populations and could not be stratified based
on available information. All ancestry was self-reported. None
of the studies used ancestry-informative markers to determine
the ancestry of the samples.
Among all the included studies, only one in the ma-
ternal group [33] and one in the fetal group [44] ex-
cluded PPROM (Table 1a and 1b). Several studies had
a gestational age (GA) cut-offs earlier than 37 weeks:
Harper et al. [36] at 28 weeks, Simhan et al. [33] and
Stonek et al. [43] at 34 weeks. Hartel et al. [37] used a
GA cut-off of 37 weeks and very low birth weight as
the PTB case criteria, thereby selecting a more severe
phenotype.
Association of genotype and phenotype
Both Cochrane's Q test and the I-square statistic suggest
that there is no evidence of heterogeneity across all studies
or for each subgroup (Figures 1 and 2), for maternal or
Table 1 Characteristics of the included studies
(a). Characteristics of the studies included for maternal genotype analysis










Women of European descent
Annells et al 2004 Australia White No GA<35 202 GA≥37 185
Hartel et al 2004 Germany White No GA<37 and VLBW 365 GA≥37 281
Hollegaard et al 2008 Denmark White No GA<37 62 GA≥37 55
Menon et al 2005 TN & PA, USA White No GA<36 101 GA≥37 326
Simhan et al 2003 PA. USA White Yes GA<34 39 GA≥37 110
Stonek et al 2008 Austria White No GA<34 21 GA≥37 1367
Heterogeneous population
Gomez et al 2010 PA, USA African American, and others No GA<37 60 GA≥37 636
Harper et al 2011 USA White, African American, Asian,
and Others
No GA<28 33 GA≥37 549
Moura et al 2009 Brazil Mulatto No GA<37 111 GA≥37 94
Moura et al 2009 Brazil Mulatto and White No GA<37 80 GA≥37 101
Simhan et al 2003 PA. USA African American Yes GA<34 12 GA≥37 46
Speer et al 2006 IL, USA White, African American, and
Others
No GA<35 79 GA≥37 80
(b). Characteristics of the studies included for fetal genotype analysis
Women of European descent
Hartel et al 2004 Germany White No GA<37 and VLBW 606 GA≥37 491
Heterogeneous population
Pereyra et al 2012 Uruguay Uruguayan No GA<37 53 GA≥37 56
Speer et al 2006 IL, USA White, African American, and
Others
No GA<35 78 GA≥37 78
Velez et al 2007 TN & PA, USA African American Yes GA<36 48 GA≥37 257
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effect model [46] was employed to pool all studies for
summary OR estimation.
For the maternal genotype analysis, the overall OR is
0.74 for genotype CC versus CG+GG (95% CI 0.58 –
0.96), demonstrating a significant protective effect of the
CC genotype. In subgroup analysis, women of European
descent have an OR of 0.68 (95% CI 0.51 - 0.91), but the
association is not significant in other populations (OR
1.01, 95% CI 0.59 – 1.75) (Figure 1 Forest plot).
For the fetal genotype analysis, the overall OR for
genotype CC versus CG+GG is 0.98 (95% CI 0.72 –
1.33). Although genotype CC showed a trend toward a
protective effect in infants of European descent, the re-
sult is not significant (Figure 2 Forest plot).
Bias assessment
For maternal genotype sensitivity analysis, the overall
OR after exclusion of any individual study showed no
change of the trend - ranging from 0.71 to 0.81 - indicat-
ing a robust protective effect of the CC genotype against
PTB. In the European descent subgroup, the sensitivityanalysis was still stable, with summary ORs ranging from
0.63 to 0.76. However, exclusion of one study [33] pro-
duced a summary OR with borderline significance (OR
0.76, 95% CI 0.57 – 1.03) (Table 2a). Interestingly, this
was the only maternal study that excluded PPROM
(Table 1a). This result suggests that PPROM may thus
be a confounding factor and deserves separate analysis
to reduce phenotypic heterogeneity. Unfortunately, we
had insufficient data to stratify by the presence or ab-
sence of PPROM. Fetal genotype sensitivity analysis also
showed no change in the trend (Table 2b).
Funnel plots were symmetrical for both the maternal
and fetal analyses, indicating no publication bias. Egger's
test [47] also showed no evidence of publication bias
(p=0.43 for maternal genotype analysis, p=0.54 for infant
genotypes) (Figures 3 and 4 Funnel plots).
Discussion
Population heterogeneity may help to explain why re-
sults among genetic studies of rs1800795 and PTB asso-
ciation were inconsistent. Indeed, HapMap data showed
that the frequency of the derived C allele of rs1800795 is
Figure 1 Forest plot for maternal genotype analysis. The count for genotypes, weight, OR, 95% confidence interval for each study; summary
for each subgroup population; and heterogeneity test statistics are shown. Each square represents an OR for each specific study, and the area is
proportional to the weight. Each horizontal line shows the 95% CI for each study. The diamonds are the summary OR for each subgroup
population or for the total. The CC genotype is significantly protective against PTB in women of European descent (OR=0.68, 95% CI 0.51 – 0.91).
It is not significant in heterogeneous populations.
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in the CEU population [45]. In other population sam-
ples, the C allele frequency is consistently high in people
of European descent, ranging from 0.35 in Tuscans from
Italy to 0.65 in a European-American sample ascertainedFigure 2 Forest plot for fetal genotype analysis. The count for genotyp
summary for each subgroup population; and heterogeneity test statistics a
study, and the area is proportional to the weight. Each horizontal line show
summary odds ratio for each subgroup population or for the total. The ass
European descent, or for those of heterogeneous populations.for coronary artery disease. In contrast, the C allele fre-
quency is consistently low in East Asian (highest in
Chinese in Metropolitan Denver, Colorado, 0.006) and
African (highest in Maasai in Kinyawa, 0.049) popula-
tions. The frequency in admixed populations varies. Thees, weight, odds ratio, 95% confidence interval for each study;
re shown. Each square represents the odds ratio for each specific
s the 95% confidence interval for each study. The diamonds are the
ociation between rs1800795 and PTB is not significant for fetuses of
Table 2 Sensitivity analysis
(a). Maternal genotype sensitivity analysis
Study omitted Overall OR Subgroup OR
Women of European descent
Annells et al 2004 0.76 [0.57, 1.01] 0.68 [0.48, 0.95]
Hartel et al 2004 0.73 [0.54, 0.98] 0.63 [0.45, 0.90]
Hollegaard et al 2008 0.72 [0.55, 0.94] 0.65 [0.48, 0.88]
Menon et al 2005 0.73 [0.56, 0.96] 0.66 [0.48, 0.90]
Simhan et al 2003 0.81 [0.63, 1.05] 0.76 [0.57, 1.03]
Stonek et al 2008 0.76 [0.59, 0.99] 0.71 [0.53, 0.94]
Heterogeneous population
Gomez et al 2010 0.74 [0.57, 0.95] 1.01 [0.57, 1.78]
Harper et al 2011 0.74 [0.57, 0.96] 1.08 [0.60, 1.96]
Moura et al 2009 -1 0.73 [0.57, 0.95] 1.00 [0.55, 1.83]
Moura et al 2009 -2 0.74 [0.57, 0.96] 1.06 [0.58, 1.93]
Simhan et al 2003 n/a n/a
Speer EM et al 2006 0.71 [0.54, 0.92] 0.88 [0.43, 1.83]
(b). Fetal genotype sensitivity analysis
Study omitted Overall OR Subgroup OR
Women of European descent
Hartel et al 2004 1.45 [0.63, 3.35] n/a
Heterogeneous population
Pereyra et al 2012 n/a n/a
Speer et al 2006 0.92 [0.66, 1.28] 1.07 [0.12, 9.39]
Velez et al 2007 0.97 [0.71, 1.33] 1.53 [0.61, 3.83]
Figure 3 Funnel plot for maternal genotype analysis. Funnel plot was
shown. Each square or diamond represents a study. Squares and diamonds
publication bias.
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panel reported a frequency of 0, a population with African
ancestry in Southwest USA had a frequency of 0.092,
while a population with Mexican ancestry in Los Angeles
had a frequency of 0.16 [48]. The allele frequency differ-
ence of 0.53 between people of European descent and
populations in other continents falls within the 5% tail of
continental allele frequency differences for a large panel of
common SNPs (see Additional file 2) and is thus statisti-
cally significant. This variation suggests that population
heterogeneity could have strong effects for this polymorph-
ism. After stratification by population, our subgroup ana-
lysis showed that the rs1800795 CC genotype is significantly
protective against PTB in women of European descent, but
not in other heterogeneous populations (Figure 1). In the
latter group of populations, ancestral diversity is likely to
obscure any potential genotype-phenotype association,
emphasizing the importance of addressing underlying
population structure in genetic studies.
A regression analysis reveals a negative relationship
between OR and CC genotype frequency (see Additional
file 3). The result is significant in maternal studies. This
matches the finding that in European populations, which
have high CC genotype frequencies, the CC genotype
has a protective effect against PTB; while in ethnically
heterogeneous populations, which have low or zero CC
genotype frequencies, no protective effect could be
observed.
In all these studies, all ancestry was self-reported. Un-
fortunately, genetic admixture data confirming self-
reported ancestry are not available. However, previousshowing OR versus standard error (SE). Egger’s test p value is also
represent different subgroup populations. There is no evidence of
Egger's test p=0.54
Figure 4 Funnel plot for fetal genotype analysis. Funnel plot showing OR versus standard error (SE). Egger’s test p value is also shown. Each
square or diamond represents a study. Squares and diamonds represent different subgroup populations. There is no evidence of publication bias.
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markers among pregnant women enrolled in clinical
studies [18]. Although we cannot exclude the possibility
of misclassification of some women, we infer a similar
high rate of concordance between self-reported race/eth-
nicity and genotyped race/ethnicity among women en-
rolled in this meta-analysis.
It is intriguing that rs1800795 has such large fre-
quency differences across different populations. In
addition to its association with PTB, this SNP has
been shown to be associated with many other diseases,
such as juvenile rheumatoid arthritis [32], susceptibility
to Kaposi sarcoma [49], metabolic syndrome [50-54],
and inflammatory bowel disease [55]. However, there is
no strong evidence of natural selection near rs1800795
[56-58].
Methodological differences may have contributed to
the inconsistent results among prior studies. Most stud-
ies compared CC vs. CG+GG, but some reported GG vs.
CG+CC and others compared individual alleles rather
than genotypes. Because of the evidence that CC geno-
types cause significantly lower serum IL-6 concentra-
tions than do the CG or GG genotypes [32], we
uniformly meta-analyzed CC versus CG+GG for all stud-
ies, providing a consistent approach to the genotype-
phenotype correlation.
Another goal of our meta-analysis was to increase stat-
istical power by increasing the sample size. For women
of European descent, we pooled 790 PTB cases and
2,324 controls, which significantly increased the sample
size relative to any previous individual study. With this
sample size, we have 97.72% power to detect an OR of
0.68 at the 0.05 significance level. Under the sameconditions, the single study with the largest case sample
size [37] had only 51.38% power.
The purpose of this meta-analysis is to pool peer-reviewed
published studies that qualify our inclusion criteria (see
Additional file 1). Even though there is no evidence of publi-
cation bias (Figures 3 and 4), a potential limitation of our
study is that some findings of no association between
rs1800795 and PTB may not have been reported in the
literature and therefore could not be included in our
meta-analysis.
In addition to population structure, phenotypic hetero-
geneity is another problem that may undermine studies
of any complex diseases. In this meta-analysis, we strati-
fied by population, included the data from earlier GA
cutoffs, and selected earlier PTB cases. Therefore, our
conclusion that the CC genotype of rs1800795 in the IL6
promoter is protective against PTB is limited to European
women with early PTB. Our sensitivity test showed that
PPROM may be a confounding factor. Besides early PTB
and PPROM, further refinement of PTB phenotype, such
as a sub-classification by placenta abruption, cervical in-
sufficiency, and other factors, may also help to reduce
phenotype heterogeneity.
Conclusions
In summary, we performed a meta-analysis of the associ-
ation between PTB and a polymorphism located in the
IL6 promoter region, SNP rs1800795. We specifically
stratified the analysis by population subgroup and se-
lected for early PTB. We found the derived CC genotype
is protective against PTB in women of European ances-
try. No significant associations were found for non-
European samples, in whom the CC genotype frequency
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A literature search was conducted in PubMed (U.S. na-
tional Library of Medicine, Jan 1966-April 2012) to identify
studies of the association between IL6 rs1800795 and PTB.
Keywords included: (“interleukin 6 polymorphism”, or
“interleukin 6 variant”, or “interleukin 6 genotype”), AND
(“preterm birth” OR “preterm delivery”). The “AND” oper-
ator was used to combine these terms in varying combina-
tions. No search software was used. After these studies
were retrieved, they were individually reviewed. Bibliog-
raphies of all articles retrieved were further reviewed for
potentially eligible studies (see Additional file 1).
Study selection and data extraction
We included human studies with: (1) a genotype of IL6
SNP rs1800795 (also referred as IL6 -174 or −237) and
(2) a collection of affected PTB cases and unaffected
controls. Two authors (W.W. and E.A.S.C) independ-
ently searched and reviewed the articles. If studies only
presented summary data, we contacted the authors for
genotype counts and population stratification as needed
(see Additional file 1). Publications were excluded if the
rs1800795 genotype distribution for cases and controls
could not be determined, or if the control group was
reported to deviate significantly from Hardy-Weinberg
equilibrium. Non-English language papers were also ex-
cluded. When two or more articles were published by
the same group of authors, we evaluated the studies for
evidence of overlapping samples. If the paper, or author
correspondence, suggested overlapping cohorts, we in-
cluded only the first study for meta-analysis. The study
population geographic origins, criteria for PTB diagno-
sis, occurrence of PPROM, sample source (maternal or
fetal), and genotype count for affected and unaffected in-
dividuals were extracted.
Selection of outcomes
All studies of PTB with GA <37 weeks were eligible for in-
clusion. If multiple GA cut-offs <37 weeks were reported, we
selected the cut-off that was one level earlier than 37 weeks
in order to ensure an accurate phenotype and to reduce
phenotype heterogeneity. This approach allows us to reduce
classification error for PTB occurring near GA=37 weeks,
and tends to select for a more severe phenotype (earlier
PTB), further helping to reduce phenotype heterogeneity.
PPROM is a distinct subset of PTB and is frequently ex-
cluded in PTB studies [26]. Exclusion of PPROM would
further reduce phenotype heterogeneity; however, among
all IL6-PTB association studies, only two excluded PPROM[33,44] (Table 1a and 1b). Therefore, study selection was
not predicated on exclusion of PPROM.
Statistical analysis
The meta-analysis compared the CC versus CG+GG ge-
notypes, based on prior functional studies that suggest a
similar phenotype for the latter two genotypes [32]. Ma-
ternal and fetal genotypes were analyzed separately. Hetero-
geneity was assessed by Cochrane’s Q test of heterogeneity
and the I-square statistic [59,60]. If there was no significant
heterogeneity, a Mantel–Haenszel fixed-effect model [46]
was employed to calculate the pooled odds ratio (OR) and
95% confidence interval (CI). Otherwise, the random-
effects model was used. Subgroup analysis was performed
to test for the effects of population stratification. Sensitivity
analysis was performed by omitting one publication at a
time. Funnel plots and Egger's test [47] were used to assess
publication bias. The analysis was carried out using
RevMan 5.0 [61], and STATA 11 [62]. This article was pre-
pared based on the guideline of “meta-analyses of observa-
tional studies” (MOOSE) [63]. A MOOSE checklist is
shown in Additional file 4 (see Additional file 4).
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reasons of inclusion or exclusion.
Additional file 2: Distribution of SNPs allele frequency differences
for three continental populations.
Additional file 3: Meta-regression analysis for (a) maternal
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